A Phase 3 interventional study of sIPV and wIPV in Poliomyelitis, sponsored by Beijing Minhai Biotechnology Co., Ltd. Completed at 1 site in China. Open to participants aged 60 Days to 89 Days, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-12-22.
Sponsored by Beijing Minhai Biotechnology Co., Ltd · Phase 3, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 18 studies testing Poliovirus Vaccine, Inactivated in Poliomyelitis — 3 open to participants now, 3 under way, none of them phase 3. Poliovirus Vaccine, Inactivated · Poliomyelitis.
Among the 18 studies testing Poliovirus Vaccine, Inactivated in Poliomyelitis, this one is the 3rd largest by enrollment, is one of 6 that started in 2017, is one of 4 in phase 3, and was the 18th registered.
275 studies on the registry are indexed under Poliomyelitis; 19 are open to participants now.
Browse Poliomyelitis studies →3 of the 18 studies testing Poliovirus Vaccine, Inactivated in Poliomyelitis are open now, in 1 country. Recruiting first, the newest first:
Sinovac Biotech Co., Ltd · Sites in China
Ages 3 mo–50 yrs · Healthy volunteers
Institute of Medical Biology, Chinese Academy of Medical Sciences · Sites in China
Ages 2 mo–2 mo · Healthy volunteers
International Centre for Diarrhoeal Disease Research, Bangladesh
Ages 42 days–48 days · Healthy volunteers
By country, each count listing its studies:
Poliovirus Vaccine, Inactivated: first FDA approval 2002 (Pediarix). What it is approved for, and how studies give it, is on its page →
Of the 11 Poliomyelitis studies recruiting now, none (0%) set no upper age limit and 11 (100%) stop at 75 or younger; 10 take children under 18; 11 take healthy volunteers.
This study: 60 Days to 89 Days · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
18 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 1 · Phase 3 4 · Phase 4 11
First in 2009; this study’s year is marked. 6 started in 2017.
This study's enrollment of 1,200 is above the median of 478 across 250 interventional studies indexed under Poliomyelitis.
Median enrollment 672 across the 18 interventional studies. Of the 11 that completed or were terminated, 3 (27%) have results posted.
This tab as a report to print or save as PDF → With an account.
6 of 18 have an industry lead sponsor. The 10 most frequent:
Beijing Minhai Biotechnology Co., Ltd is the lead sponsor of 10 studies on the registry; 1 is open to participants now.
Beijing Minhai Biotechnology Co., Ltd has 2 studies filed under Poliomyelitis — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 18 studies testing Poliovirus Vaccine, Inactivated in Poliomyelitis, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The study aimed to evaluate the safety and immunogenicity of a Sabin strain-based inactivated polio vaccine in infants aged two months (60\~89 days).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
600 participants
Biological: sIPV
600 participants
Biological: wIPV
sIPVs were developed by Biominhai (Beijing Minhai Biotechnology Co. Ltd.)
wIPVs were developed by Sanofi Pasteur
the seroconversion rates of poliovirus type I, type II and type III neutralizing antibodies
Time frame: 30 days after the primary immunization
Plan to share: No
No publications or documents are linked to this record.
Ran from Aug 2017 to primary completion in Apr 2023, 67 months.
Of 36 industry-sponsored phase 3 interventional studies under Poliomyelitis, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 21. This study's 67 months is above that.
Counting every sponsor, half of 45 studies reached it within 12 months; a quarter within 7 and three quarters within 21.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Poliovirus Vaccine, Inactivated
Beijing Minhai Biotechnology Co., Ltd